medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2003, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2003; 1 (2)

Suppresive therapies in herpes simplex

González GSE

Language: Spanish
References: 23
Page: 113-115
PDF size: 92.74 Kb.


ABSTRACT

Genital herpes (GH) is caused by Herpes Simplex virus 1 and 2 (HSV-1, HSV-2). It is sexually transmitted with a high worldwide incidence and prevalence. The suppressive therapies have achieved a decreased in clinical recurrences as well as a decrease in the transmission to healthy couple (discordant couples). The most common indications of therapy are: severe and frequent recurrences that are stressful for the patient, severe and complicated prodromes, decreased risk of transmission to healthy couple as well as diminished psychological and psychosocial problems, and also immunocompromised hosts. Acyclovir has been used for long periods of treatments (more than 10 years). Valacyclovir and famcyclovir are the two other drugs used for this type of therapy. In a recent study valacyclovir showed to be useful in decreasing the transmission of the infection to the healthy couple. A curative treatment is yet the unreachable goal and it is seen still far away, but new antiviral, vaccines and immunological therapies are under investigative trials


REFERENCES

  1. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a methaanalysis. J Infect Dis 2002; 185: 45-52

  2. Brookes JL, Haywood S, Green J. Adjustment to the psychological and social sequelae of recurrent genital herpes simplex infection. Genitourin Med 1993; 69 (5): 384-387

  3. Lafferty WE. The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes 2002; 9: 2

  4. Bossi P. Genital herpes: epidemiology, transmission, clinic, asymptomatic viral excretion, impact on other sexually transmitted diseases, prevention, and treatment. Ann Dermatol Venereol 2002; 129 (4 Pt 2): 477-493

  5. Roberts CM, Pfiester JR. Increassing proportion of HSV-1 as a cause of genital herpes infection in college students. Abstracts, 2002 National STD Prevention Conference; March 4-7, 2002; San Diego, California. LB1

  6. Forward KR. Recovery rates of herpes simplex tipe 1 (HSV-1) from patients with genital herpes in Nova Scotia. 42nd Annual Interscience Conference of Antimicrobial Agents and Chemoterapy; September 27-30, 2002; San Diego, California. L-771.

  7. Stanberry L, Cunningham A, Mertz G et al. New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res 1999; 42 (1): 1-14

  8. Cunningham AL, Flexman JP etal. Manual clínico de herpes genital. Science Press Ltd. Londres, United Kingdom. 1998

  9. Barton SE, Ebel CE, Kirchner JT, Mertz GJ. The clinical management of recurrent genital herpes: current issues and future prospects. Herpes 2002; 9 (1): 15-20

  10. Naesens L, De Clercq E. Recent developments in herpes virus therapy. Herpes 2001; 8: 1

  11. Strand A. Long-term supressive therapy for genital herpes in the immunocompetent host. Herpes 1999; 6: 1

  12. Patel R, Boselli F, Cairo I, Barnett G, Price M, Wulf HC. Patients’ perspectives on the burden of recurrent genital herpes. Int J STD AIDS 2001; 12 (10): 640-645

  13. Scott LL, Hollier LM, McIntire D et al. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial. Infect Dis Obstet Gynecol 2001; 9 (2): 75-80

  14. Scott LL, Sánchez PJ, Jackson GL et al. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996; 87 (1): 69-73

  15. Scott LL, Alexander J. Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy. Am J Perinatol 1998; 15 (1): 57-62

  16. Braig S, Luton D, Sibony O et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol 2001; 96 (1): 55-58

  17. Brocklehurst P, Kinghorn G, Carney O et al. A randomized placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynecol 1998; 105 (3): 275-280

  18. Watts H, Brown Z, Corey L, Zeh J. Acyclovir suppression to prevent cesarean deliveryafter first-episode genital herpes. Obstet Gynecol 1996; 87 (6): 1064-1065

  19. Aoki FY. Management of genital herpes in HIV-infected patients. Herpes 2001; 8 (2): 41-45

  20. Mattison HR, Reichman RC, Bolgiano D et al. Double-blind placebocontrolled trial comparing long-term suppressive with short term oral acyclovir therapy for management of genital herpes. Am J Med 1988: 83: 20-25

  21. Honda M, Okuda T, Hasegawa T, Kurokawa M, Shiraki K, Matsuo K, Komatsuzaki M, Niimura M. Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2. Antivir Chem Chemother 2001; 12 (4): 233-239

  22. Reitano M, Tyring S, Lang W et al. Valaciclovir for the supression of recurrent genital herpes simplex virus infections: a large scale dose range-finding study. J Infect Dis 1998; 178, 603-610

  23. Diaz-Mitoma F, Sibbald RG, Shafran SD et al. Oral famciclovir for the supressive therapy of recurrent genital herpes: a ramdomized controled trial. JAMA 1998; 280: 887-892




2020     |     www.medigraphic.com